PAEDIATRICS

Not currently approved for paediatric use.

ELDERLY

The frequency of serious infection among Xeljanz-treated subjects 65 years of age and older was higher than among those younger than age 65.

Safety has not been determined.

Use with caution in the elderly.

PREGNANCY
NEW GLOBAL
GUIDELINES

For access to the full guidelines click here

Women with inflammatory bowel disease should discontinue tofacitinib at least 4 weeks prior to conception unless there is no effective alternative therapy to maintain maternal health.17

BREASTFEEDING

Mothers with IBD currently on JAKi should not breastfeed.17